https://beckleypsytech.com

Beckley Psytech · Working with patients in mindBeckley Psytech · Working with patients in mind AboutResearchTrialsNewsImpactTeamContact usWorking withpatients in mindSelf Reflected by Greg DunnOurMissionWe are dedicated to helping people suffering from neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines.OurResearchBeckley Psytech’s innovative approach to helping patients in need is focused on developing novel psychedelic therapies to improve patient outcomes.More about our workCompoundsProgressing innovative formulations and applications of psychedelic agents such as 5-MeO-DMT, psilocin and other compoundsPsychological SupportLeveraging personalised psychological support to target clinically meaningful improvements in a less time and resource intensive wayDigitalDesigning digital tools that deliver a holistic and differentiated solution to optimise patient outcomesOurStoryFor our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and intergenerational vocation.More about usOurLeadershipTeamCosmo Feilding MellenCEOCosmo is a drug development entrepreneur dedicated to unlocking the medical potential of psychoactive substances in order to help patients in need. Cosmo has worked closely with the Beckley Foundation for over 10 years and, in 2016, he co-founded Beckley Research & Innovations to develop ethical business models focused on scientific research into medical cannabis and psychedelics. Cosmo subsequently served as Co-Founder and Managing Director of Beckley Canopy Therapeutics, a cannabis-based drug development company, and Spectrum Biomedical UK, a medical cannabis distribution company. In 2019, both of these companies were acquired by Canopy Growth Corporation, the world’s largest medical cannabis company.Dr. Rob ConleyChief Scientific and Medical OfficerDr. Rob Conley is the Chief Scientific Advisor at Beckley Psytech. He previously served as Senior Vice President at Eleusis and Chief Science Officer, Neuroscience at Eli Lilly and Co. Prior to that he had a long academic career, first at the University of Pittsburgh and then at the University of Maryland School of Medicine. He remains an Adjunct Professor of Psychiatry and Psychopharmacology at Maryland. Rob holds an MD from the University of Maryland School of Medicine and a BA from Johns Hopkins University. He completed a Psychiatry residency at the University of Pittsburgh, where he served as the Chief Resident. Rob is also a Fellow of the American College of Neuropsychopharmacology.Dr. Fiona DunbarChief Medical AdvisorFiona Dunbar is a Pharmaceutical Physician and the former Vice President of Global Medical Affairs and Patient Engagement at Janssen (the pharmaceutical division of Johnson & Johnson). During her 29-year career at Janssen, Fiona held positions of increasing responsibility within Research & Development and Medical Affairs. She contributed to drug development across a range of therapeutic areas including neurosciences, immunology, oncology and infectious diseases, and was involved in the development of Esketamine (Spravato), the first psychedelic-based psychiatric drug to be licensed by the FDA (2019). A native Zimbabwean and dual citizen of Canada and Great Britain, Fiona brings an international perspective to her work. Prior to joining the pharmaceutical industry, she was a Medical Officer at the South African Institute of Medical Research. She holds an MB BCh from the University of the Witwatersrand, South Africa and is a Fellow of the Faculty of Pharmaceutical Medicine. Becky VerityChief Commercial OfficerBecky is an engineering graduate who holds an MBA and has worked for more than 18 years in the pharmaceutical industry. Holding executive positions at regional and local operating company level within Johnson & Johnson, Becky is an experienced commercial leader who has lead teams working across multiple therapy areas, with an in depth knowledge of market access, commercial strategy and go to market models. Becky has experience in digital transformation in healthcare and a passion for the opportunity that this presents to optimise outcomes for both patients and the healthcare system.Michael NorrisChief Financial OfficerExperienced CFO with a demonstrated history of working in public markets and private equity. Skilled in Fundraising, IPOs, Turnarounds, Business Planning, Mergers & Acquisitions and with a sector focus on eCommerce, Technology and Biomedical. Strong entrepreneurial background and a Fellow of the Chartered Institute of Management Accountants.Matt HartleyChief Operating OfficerMatt Hartley is an experienced strategy and operations executive, having held senior positions at a number of biotech startups working across modalities (small molecule, gene therapy, medical devices) and therapy areas (CNS, ophthalmology, oncology). He also has experience as founder and CEO of a technology startup where he spent 6 years developing and running globally deployed patient companion platforms for MNC pharma clients such as Bayer. A stint as a pharma analyst at Morgan Stanley and Citibank at the beginning of his career keeps him sensitive to commercial considerations.Tim MasonChief Development OfficerA science and business graduate, Tim is a pharmaceutical professional with over 18 years’ experience working with both small start-ups and large pharmaceutical companies. Tim has a keen passion for integrating naturally derived medicines with evidenced based clinical development. Having formerly served as Head of Clinical Development for Beckley Canopy Therapeutics and as an advisor to the Beckley Foundation, Tim is an experienced cannabis and psychedelic-based drug developer with a strong focus on efficient delivery of projects from preclinical to commercialisation.Meet the teamNewsandviewsAugust 7, 2024Beckley Psytech appoints Dr Rob Hershberg to its Board of DirectorsDr. Hershberg is Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors at Hillevax Inc., a NASDAQ-listed biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. He is also a Venture Partner with Frazier Healthcare Partners and has been working with Frazier and its portfolio companies as an Entrepreneur-in-Residence, Senior Advisor, and executive for the last 14 years. Alongside news of Dr Hershberg’s appointment, Beckley Psytech also announced that Lady Amanda Feilding, Co-Founder of Beckley Psytech, will be stepping down from the Board in order to focus her work as Executive Director of The Beckley Foundation. She will continue supporting the Beckley Psytech team as a senior scientific and strategic advisor. Read moreAugust 7, 2024Beckley Psytech announces initial results from Phase I study and first patients dosed in Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive DisorderThe Phase IIa trial is an open-label study investigating ELE-101 as a potential new treatment for Major Depressive Disorder (MDD), commonly known as depression. The study will evaluate the safety, tolerability, subjective effects and efficacy of a single intravenous dose of ELE-101 in patients with depression. The dose for the study was selected using preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data from Beckley Psytech’s Phase I double-blind, placebo-controlled, randomised study of ELE-101 in healthy participants. That data showed that ELE-101 was well-tolerated with a dose-proportional pharmacokinetic profile and reliable induction of high-intensity, short-duration psychedelic experiences.Read moreAugust 7, 2024Beckley Psytech and PsyPAN launch Participant Impact Report and Peer Support Pilot ProgramBeckley Psytech and PsyPAN have published a new Impact Report which shares novel insights from psychedelic clinical trial participants. The report highlights the desire for post-trial support and introduces a peer support pilot program for participants. Beckley Psytech has given PsyPAN an unrestricted grant to initiate the 12-month pilot program aimed at supporting trial participants in the UK.Read moreAugust 7, 2024First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brainThe study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic intranasal formulation of the psychedelic 5-MeO-DMT. In the study, healthy volunteers will be given both placebo and a 12 mg dose of BPL-003 on separate study visits over a period of 1 month while undergoing a high-density electroencephalogram (HD-EEG) scan to measure the electrical activity in the brain in order to better understand how 5-MeO-DMT elicits its profound consciousness-altering effects. The trial is being overseen by Dr. Christopher Timmermann and Dr David Errtizoe from the Centre for Psychedelic Research at Imperial College London and is funded through a research grant from Beckley Psytech. Initial results are expected in 2026. Read moreRead all newsBeckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression AboutResearchNewsImpactTeamCareersContact© 2024 Beckley Psytech. All rights reserved.Privacy PolicyCookie PolicySubscribe to our newsletterThank you for subscribing!Something went wrong while submitting the form. Please try again.You are leaving Beckley PsytechLinks to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.CloseI understand1728951541https://beckleypsytech.com

Guhindura urubuga rwawe?

Uriko ukora iki?